Zim Laboratories' Q1 FY27 Total Operating Income grew 31.2% YoY to ₹94.2 Cr.

EBITDA dropped 40% to ₹3.4 Cr (3.7% margin) due to higher costs, resulting in a ₹4.0 Cr net loss.

Innovative product revenue tripled YoY to ₹13.8 Cr.

CAPA remediation is largely complete, with 17 filings and 10 approvals secured.